What is the recommended prednisone (40 mg) taper schedule for treating an acute exacerbation of chronic obstructive pulmonary disease (AECOPD)?

Prednisone 40 mg Taper for AECOPD

Give prednisone 40 mg daily for 5 days without a taper—this is the evidence-based standard for treating acute exacerbations of COPD. 1

Dosing Regimen

The 2017 ERS/ATS guidelines, citing the 2014 GOLD recommendations, explicitly state: "A dose of 30–40 mg prednisone per day for 5 days is recommended" for AECOPD 1. This is a fixed 5-day course—not a taper. You give the full 40 mg dose each day for 5 consecutive days, then stop.

Key Implementation Points:

• Duration: 5 days total (not 7, not 14 days)
• Dose: 40 mg daily (no dose reduction during the 5 days)
• Route: Oral administration is equivalent to IV 1
• Timing: Administer in the morning before 9 AM to minimize HPA axis suppression 2
• No taper needed: After 5 days, simply discontinue—no gradual taper is required for this short duration 2

Evidence Supporting 5-Day Course

The REDUCE trial 3 definitively demonstrated that 5 days of prednisone 40 mg is non-inferior to 14 days for preventing re-exacerbation within 180 days (HR 0.95,90% CI 0.70-1.29). Critically, the shorter course reduced total glucocorticoid exposure from 793 mg to 379 mg (P < .001) without increasing treatment failure rates.

The guidelines acknowledge that even shorter durations (3 days) may be effective in hospitalized patients, but 5 days remains the standard recommendation with the strongest evidence base 1.

Clinical Context

For ambulatory patients: The ERS/ATS recommends a short course (≤14 days) of oral corticosteroids, with 5 days at 40 mg being the preferred regimen 1.

For hospitalized patients: The same 5-day, 40 mg regimen applies. One study used 60 mg for 5 days followed by a taper (total 10 days) 1, but the simpler 5-day course without taper is now standard and reduces unnecessary steroid exposure.

For ICU patients: Recent data 4 suggests short-course (≤5 days) tapers reduce hospital length of stay (7 vs 11 days, P < .0001) without increasing treatment failure compared to extended courses.

Important Caveats

Blood Eosinophil Count Consideration

Emerging evidence suggests that patients with blood eosinophils ≥2% respond better to corticosteroids (11% treatment failure rate) compared to those with eosinophils <2% (26% failure rate with prednisone vs 20% with placebo) 1. However, this should not prevent you from prescribing steroids—the guidelines still recommend treatment for all AECOPD patients, but this biomarker may help predict response.

When NOT to Use This Regimen

The FDA label 2 emphasizes that dosing must be individualized, and the 5-day course applies specifically to acute exacerbations. If the patient has been on long-term corticosteroid therapy (weeks to months), abrupt discontinuation is contraindicated and a gradual taper is required to prevent adrenal insufficiency.

Real-World Prescribing Gap

A 2022 study 5 found that only 2.1% of patients received the appropriate dose AND duration at a major academic center, with most receiving excessive courses. This inappropriate prescribing was associated with increased hyperglycemia (50.5%), hypertension (6.8%), and higher 30-day (24.2%) and 90-day (41.1%) readmission rates.

Contradictory Evidence

One 2023 primary care trial 6 found no benefit of prednisone over placebo (42% vs 34.5% treatment failure, p=0.25), and actually showed higher respiratory-related failures with prednisone (27.6% vs 13.6%, RR 2.00, p=0.015). However, this study was underpowered (43% of planned enrollment) and conflicts with the broader evidence base and guideline recommendations. The weight of evidence and guideline consensus supports using corticosteroids.

Practical Algorithm

1. Confirm AECOPD diagnosis (increased dyspnea, cough, and/or sputum production beyond day-to-day variation)
2. Check blood eosinophils if available (≥2% predicts better response, but treat regardless)
3. Prescribe prednisone 40 mg PO daily × 5 days
4. Instruct patient to take in the morning with food
5. Add bronchodilators and antibiotics as indicated
6. Stop after day 5—no taper needed
7. Monitor for hyperglycemia if diabetic
8. Reassess maintenance COPD therapy post-exacerbation